Immunovant stock price target cut to $5 from $7 at UBS

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Immunovant Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply